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Abstract: Epilepsy is a common pediatric neurologic disorder that is difﬁ  cult to manage in a 
substantial portion of children. Levetiracetam (LEV) is a novel antiepileptic drug (AED) that 
has recently been approved as add-on treatment for various seizure types in epilepsy popula-
tions that include children: for refractory partial seizures in epilepsy patients 4 years old, for 
myoclonic seizures in juvenile myoclonic epilepsy patients 12 years old, and for primary 
generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (6 years old with 
FDA approval; 12 years old with EMEA approval). A review of published pediatric studies 
indicates that the efﬁ  cacy of LEV is best established for partial seizures; however, results from 
recent double-blind and open-label trials indicate that adjunctive LEV also controls generalized 
seizures – particularly myoclonic and generalized tonic-clonic – in children and adolescents with 
primary generalized epilepsy. LEV was well-tolerated in pediatric studies. The most common 
adverse events (AEs) reported were sedation related. Behavioral AEs were among the most 
commonly reported events in some trials; conversely, improvements in behavior and cogni-
tion were also frequently reported. LEV appears to be a safe and effective AED with unique 
characteristics that beneﬁ  t the treatment of children with epilepsy.
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Introduction
Epilepsy is a common neurologic disorder in children and frequently presents a 
signiﬁ  cant challenge for treatment (Shinnar and Pellock 2002). Seizures are refrac-
tory in about a quarter of children (Pellock 1999) and pediatric epilepsy often occurs 
in the context of mental retardation (Shinnar and Pellock 2002) or signiﬁ  cant behav-
ioral problems (Ott et al 2003). Children with refractory epilepsy may receive trials 
of several antiepileptic drugs (AEDs) without achieving adequate seizure control or 
acceptable tolerability (Herranz 2003; Grosso et al 2005; Mandelbaum et al 2005; 
Opp et al 2005). Despite the availability of a number of AEDs that are approved for 
pediatric use, additional AEDs that are effective and well-tolerated in children are 
still needed. Levetiracetam (LEV) was recently approved for use as add-on therapy 
in children with partial seizures and now provides another alternative in the treatment 
of pediatric epilepsy.
LEV is a broad-spectrum AED with a unique preclinical and pharmacological 
proﬁ  le. In rodent studies, it demonstrated no activity in traditional acute seizure models 
(maximal electroshock and pentylenetetrazol seizure tests) but exhibited potent seizure 
protection in chronic epilepsy models, ie, in kindled animals and in genetic models 
of generalized epilepsy. It was also protective against seizures in rodent models of 
chemoconvulsant-induced partial seizures. LEV exhibited antiepileptogenic proper-
ties through its ability to inhibit the development of kindling in mice and rats and 
demonstrated a high safety margin compared with other AEDs in genetic models and 
kindled animals (Klitgaard 2001).Neuropsychiatric Disease and Treatment 2007:3(4) 410
Wheless
The molecular mechanisms through which LEV exerts 
its antiepileptic effects are not fully known but are unlike 
those of any other AED. LEV binds to a unique binding 
site in the brain, the synaptic vesicle protein SV2A. The 
function of this protein is still under investigation, but cur-
rent evidence suggests that it modulates synaptic vesicle 
fusion and the consequent release of neurotransmitter into 
the synapse. Because LEV does not appear to affect normal 
brain physiology, it is believed to modulate SV2A function 
only under pathophysiologic conditions (Lynch et al 2004). 
LEV is also known to selectively inhibit N-type calcium 
channels (Lukyanetz et al 2002) and to block the inhibition 
of GABA- and glycine-gated currents by negative allosteric 
modulators (Rigo et al 2002). Whether LEV’s binding at 
SV2A proteins mediates these mechanisms is unknown 
(Lynch et al 2004).
LEV has been FDA approved since 1999 for adjunctive 
treatment of refractory partial seizures in adults (Leppik 
2001) and in 2005, that approval was extended to include 
children 4 years old (Medical News Today 2005). Most 
recently, the approval was further broadened to include 
adjunctive treatment of myoclonic seizures in adults and 
adolescents 12 years of age with juvenile myoclonic 
epilepsy and adjunctive treatment of primary generalized 
tonic-clonic (PGTC) seizures in adults and children 6 
years of age with idiopathic generalized epilepsy. EMEA 
indications are similar, except that the age range approved 
for PGTC seizures is 12 years, and LEV is also approved as 
monotherapy in adults with newly diagnosed partial seizures 
(BioSpace Beat 2007). LEV, as add-on therapy, has also 
demonstrated efﬁ  cacy for refractory idiopathic generalized 
epilepsies in open-label trials that included adult patients with 
myoclonic, tonic-clonic, and absence seizures (Krauss et al 
2003; Coppola et al 2004; Kumar and Smith 2004).
Although the efﬁ  cacy, safety, and tolerability proﬁ  le of 
LEV is well established in the treatment of adult epilepsy 
patients, data in children are somewhat limited. This article 
reviews available published data on LEV in the treatment of 
pediatric epilepsy, including pertinent information on LEV’s 
pharmacokinetics, formulations, efﬁ  cacy, and safety.
Pharmacokinetics of LEV in adults 
versus children
The pharmacokinetic proﬁ  le of LEV as demonstrated in 
adults is very favorable and allows for easy titration and use 
of the drug, even in the presence of comedications. LEV is 
rapidly absorbed after oral dosing and exhibits linear kinetics 
with minimal protein binding (<10%). Oral bioavailability 
is almost 100% with peak plasma concentrations achieved 
after 1 hour and LEV has a half-life of 6–8 hours in adults 
(Patsalos, 2000). In a rat model, the half-life of LEV in 
brain extracellular ﬂ  uid was ∼50% longer than in serum and 
may explain its long duration of effect and need for only 
twice-a-day dosing (Tong and Patsalos 2001). LEV is not 
metabolized hepatically but is eliminated renally, primarily 
as unchanged drug. The half-life is extended to 10–11 hours 
in the elderly because of age-associated reduction in renal 
function. (Patsalos 2000) LEV is not known to participate 
in clinically relevant pharmacokinetic drug-drug interactions 
(Perucca 2006).
The pharmacokinetic proﬁ  le of LEV appears similar in 
pediatric patients compared with adults, except that the drug 
is cleared more quickly. Body clearance is 30% to 40% higher 
and the half-life is decreased to about 6 hours. Higher doses 
of LEV (on a mg/kg basis) may be required in children to 
accommodate their increased clearance (Pellock et al 2001). 
The product labeling recommends a starting dose in children 
of 20 mg/kg/day, and the daily dose can be increased every 
2 weeks to a maximum of 60 mg/kg/day. Similar to adults, 
the pharmacodynamic action of LEV in children appears 
prolonged relative to its plasma half-life and twice-daily 
dosing is recommended (Keppra 2004).
LEV is currently available as an oral tablet (250, 500, 
and 750 mg in the US and EU; 1000 mg in the EU only), 
a 10% oral solution (100 mg/mL), and an i.v. formulation 
(100 mg/mL). The solution is grape ﬂ  avored and contains 
no alcohol or sugar (Keppra 2004). The oral formulations 
are bioequivalent and can be used interchangeably (Coupez 
et al 2003). Children weighing less than 20 kg will need to 
initiate treatment with the oral solution to achieve their lower 
dose requirements. Oral LEV can be administered with or 
without food (Keppra 2004). The i.v. formulation is also 
bioequivalent and can be used interchangeably with the oral 
formulations; however, the FDA approval was applicable 
only for use in adult patients (Medical News Today 2006; 
Ramael et al 2006).
Efﬁ  cacy of LEV as adjunctive 
therapy in pediatric epilepsy
Prospective studies in partial seizures
Two prospective trials have evaluated the efﬁ  cacy of LEV 
for refractory partial seizures in children. The ﬁ  rst trial was 
a multicenter, prospectively designed, open-label trial that 
enrolled 24 children aged 6–12 years (Glauser et al 2002). Neuropsychiatric Disease and Treatment 2007:3(4) 411
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During a 4-week baseline period, patients received a stable 
dose of one standard AED and were required to have at least 
2 seizures. During the titration period, LEV was added to 
the baseline regimen at 10 mg/kg/day (bid dosing) and was 
increased to a maximum of 40 mg/kg/day over 6 weeks. 
After titration, patients entered an 8-week evaluation phase 
where LEV dose remained constant. Twenty-three patients 
entered the evaluation phase and were included in the efﬁ  cacy 
analysis.
The mean age of patients was 9.4 ± 2.2 years and the 
most commonly reported partial seizure subtype was complex 
partial with 83.3% of patients reporting them at baseline. 
Over half (52.2%) of the patients showed a 50% reduction 
in partial seizures from baseline, and a 75% reduction was 
documented in 21.7%. Two patients (8.7%) were seizure free 
throughout the 8-week evaluation period. Figure 1 depicts the 
median percentage reduction in seizures by seizure subtype. 
Based on this endpoint, LEV appeared to be most effective 
for secondarily generalized seizures (Glauser et al 2002).
After these positive ﬁ  ndings were reported in the prelimi-
nary open-label study, a double-blind, placebo-controlled 
study was implemented. Children (4–16 years) with at least 
8 partial seizures reported during an 8-week baseline were 
randomized to receive placebo or LEV 60 mg/kg/day bid 
(Glauser et al 2006). Patients had uncontrolled seizures on 
1 or 2 standard AEDs during baseline, and LEV or placebo 
was added to the baseline regimen. Drug was titrated over a 
4-week period (in 20 mg/kg/day increments every 2 weeks to 
a target dose of 60 mg/kg/day) after which patients entered 
a 10-week evaluation phase. The titration and evaluation 
periods were considered the treatment period, and efﬁ  cacy 
endpoints were calculated over this entire 14-week period. 
One hundred ninety-eight patients were evaluable for efﬁ  cacy 
(LEV = 101; placebo = 97). The mean age was 10.2 years 
in the LEV group and 9.8 years in the placebo group. LEV 
signiﬁ  cantly reduced weekly partial seizure frequency (the 
primary endpoint) by 26.8% over placebo (p = 0.0002). Fig-
ure 2 shows response rates based on weekly percent reduction 
in partial seizure frequency. A 50% or greater reduction in 
partial seizures was attained in 44.6% of the LEV group and 
19.6% of the placebo group (p = 0.0002). Seizure freedom 
rates were also higher in the LEV group (7% vs 1% for 
placebo). This study was the basis for the FDA’s approval 
of LEV’s use in children.
Prospective studies in partial 
and/or generalized seizures
Several prospectively designed, open-label studies have 
tested the effects of LEV in children with various epilepsy 
syndromes or epilepsy types. These studies report efﬁ  cacy 
for both partial and generalized seizures. In the ﬁ  rst published 
study, 39 patients (mean age 8.6 years) were followed for 
up to 9 months (Wheless and Ng 2002). LEV was titrated 
over 8 weeks (on average) to a mean maintenance dose of 
53.3 mg/kg/day (given bid or tid). The mean number of con-
comitant AEDs was 1.6. Seizures were reduced by >50% in 
33.3% of patients, by >90% in 23.1% of patients, and 7.7% 
of patients were seizure free. An analysis by seizure type 
indicated that efﬁ  cacy was better in partial seizures than in 
generalized seizure subtypes. In another small trial (n = 21) 
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in refractory epilepsy, Lagae and colleagues enrolled children 
from the age of 11 months to 14 years (Lagae et al 2003). 
This population included children with identiﬁ  able lesions 
on MRI, children with Lennox Gastaut or West syndrome, 
and children with idiopathic partial or generalized epilepsy. 
Most patients (17/21) were receiving at least 2 AEDs at 
inclusion. LEV was titrated from 10 mg/kg/day to a maxi-
mum of 60 mg/kg/day with dose increases occurring every 
4th day. There was a signiﬁ  cant reduction in total seizure 
frequency (from baseline) overall (p < 0.01) and 10 patients 
(47%) had at least a 50% reduction in all seizures. One child 
was seizure free (4.8%). Efﬁ  cacy did not appear to differ 
based on syndrome or epilepsy type. Sixty percent (3/5) 
of children with Lennox Gastaut and the 1 child with West 
syndrome responded well. Similarly, seizure type did not 
predict efﬁ  cacy. The response rate was roughly 50% whether 
patients had partial seizures only, generalized seizures only, 
or experienced both seizure types.
Two larger studies found generally similar results with 
LEV as adjunctive therapy. Grosso et al studied 110 children 
(6 months to 16 years old) with refractory epilepsy (Grosso 
et al 2005). Patients were followed for 2–20 months and the 
median LEV dose was 38 mg/kg/day. The overall response 
rate (≥50% reduction in seizures from baseline) was 39%, and 
9% of children were seizure free. Response rate in patients 
with partial seizures was somewhat higher than in those 
with generalized seizures (58% vs 37%). Response rates in 
patients with Lennox Gastaut or West syndrome was lower 
than in the Lagae et al study noted above (2/8 with Lennox 
Gastaut and 1/5 with West Syndrome responded). A later 
study performed by Lagae and others evaluated adjunctive 
LEV (12–62 mg/kg/day) in 67 children with a median age 
of 8 years (Lagae et al 2005). Most (76%) of these children 
were receiving 2 or more concomitant AEDs. Overall, there 
was a median percent reduction in seizures of 50% and 
49% of patients were responders (>50% seizure reduction). 
Five percent were seizure free. Response rate was similar 
in patients with either generalized or partial seizures (14 of 
32 patients with generalized seizures responded vs 16 of 31 
patients with partial seizures). The response rate was 75% 
in patients with mixed seizure types (n = 4). As in the earlier 
Lagae et al study, the etiology of epilepsy did not predict 
efﬁ  cacy.
Retrospective studies in partial 
and/or generalized seizures
A number of centers have retrospectively reviewed charts 
or databases to extract data on the use of LEV as add-on 
therapy in children with epilepsy. The largest of these 
evaluated efﬁ  cacy in 209 patients (under the age of 18) for 
a minimum of 12 weeks (Opp et al 2005). These patients 
had highly refractory seizures and had been treated with as 
many as 20 different AEDs before receiving LEV as add-on 
therapy. A response (>50% reduction in seizure frequency) 
was achieved in 25% of patients and 6% were rendered sei-
zure free. There were no signiﬁ  cant differences in outcome 
based on the type of epilepsy syndrome (generalized versus 
focal epilepsy) or its etiology (symptomatic, idiopathic, or 
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cryptogenic). However an analysis of seizure type determined 
that secondarily generalized tonic-clonic and simple partial 
seizures were best controlled by LEV, followed by general-
ized tonic-clonic, complex partial, myoclonic, tonic, absence, 
and atonic seizures.
Three smaller retrospective studies reported better re-
sponse rates than those reported by Opp et al (2005). Herranz 
and colleagues studied 43 patients under the age of 18 (mean 
age = 5.2 ± 4.4 years) who had been treated with LEV as 
add-on therapy (to 1–3 AEDs) for over 6 months (Herranz et 
al 2003). The predominant seizure type reported at baseline 
was partial onset (74% of seizures), and the mean LEV dose 
was 45 ± 33 mg/kg/day. Sixty-ﬁ  ve percent of patients had 
seizure frequency reduced by >50%, and 14% of patients 
were seizure free. The authors noted that LEV was especially 
effective for partial seizures, but also exhibited efﬁ  cacy in 
generalized seizures (tonic-clonic, absence, and myoclonic). 
In another study, Mandelbaum et al studied 59 patients aged 
9 months to 23 years for up to 12 months (Mandelbaum et al 
2005). Most patients received from 1 to 5 AEDs in addition 
to LEV, but 8 children received LEV as monotherapy. After 
12 months, 53% of patients had seizure reductions of at least 
50%, and 20% were seizure free. In this study, response rates 
were a bit higher in patients with predominantly generalized 
seizures or with mixed seizure types, than in those with focal 
seizures (55% [generalized] and 62% [mixed] versus 40% 
[focal]).
Another small retrospective study focused on younger 
children only (Tan and Appleton 2004). A computerized 
hospital pharmacy database (from a tertiary pediatric epi-
lepsy center) was searched to obtain records on young chil-
dren who were treated with LEV for epilepsy. Twenty-six 
children under the age of 11 years (median age = 7 years) 
were identiﬁ  ed and included in the study. Patients received 
between 1 and 3 AEDs in addition to LEV, which was ad-
ministered at a mean maintenance dose of 36.9 mg/kg/day. 
Sixty-one percent of children were responders (50% 
seizure reduction), and 2 (8%) were seizure free. Response 
was high across most partial and generalized seizure types, 
but was highest in patients with partial seizures, epileptic 
spasms, tonic, or atonic seizures. Response was lowest for 
myoclonic seizures.
Retrospective studies in rare epilepsy 
syndromes
Two studies were identiﬁ  ed in the literature that retrospec-
tively evaluated LEV in children with rare epilepsy syn-
dromes. Aeby and colleagues reviewed charts on 12 children 
(4–14 years old) who had epilepsies with continuous spikes 
and waves during slow-wave sleep (CSWS) (Aeby et al 
2005). All patients had neuropsychological problems, and 
most were moderately or severely mentally retarded. These 
patients received LEV (50 mg/kg/day) in addition to their 
usual AED therapy. After 2 months, signiﬁ  cant to dramatic 
improvements on EEG were noted for 7 patients (58%). 
Nine patients (75%) showed improvements in behavior 
and/or cognitive function. However, of the eight patients 
who continued on LEV for 1 year, 4 relapsed between 9 and 
11 months after LEV initiation.
Another study evaluated LEV in patients with tuberous 
sclerosis complex (Collins et al 2006). Patients with this 
inherited disorder have pathologic features of brain dysgen-
esis such as cortical and subependymal nodules, and about 
80% have epilepsy (Shorvon 2000). In this study, 20 children 
and adolescents (2–19 years old) with tuberous sclerosis 
received LEV as adjunctive therapy for up to 6 months. The 
average seizure frequency at baseline was 120 per month, and 
the most common seizure type was complex partial seizures. 
LEV was dosed in the range of 8 to 135 mg/kg/day (given 
bid or tid). A positive response (>50% reduction in seizures) 
was attained in 40% of patients, and 20% became seizure 
free (Collins et al 2006).
Efﬁ  cacy of LEV as add-on treatment 
in primary generalized epilepsy
Results of the placebo-controlled, double-blind study of 
adjunctive LEV in juvenile myoclonic and absence epilepsies 
that was the basis for regulatory approval have been reported 
in abstract form (Andermann et al 2005). Although this study 
enrolled adults as well as adolescents (age range = 12–65 
years), the results are relevant to the treatment of pediatric 
epilepsy given the high prevalence of these epilepsies and 
their typical onset age (early adolescence). In this study, 
patients who were poorly controlled on 1 AED at baseline 
were titrated to LEV 1500 mg bid or placebo over 4 weeks 
and then entered a 12-week stable dose period. Responder 
rate (percentage of patients with ≥50% reduction in days 
with myoclonic seizures versus baseline) was calculated over 
the entire 16-week treatment period. The responder rate was 
58.3% in the LEV group (n = 60) vs 23.3% in the placebo 
group (n = 60) (p = 0.0002). The median difference between 
groups in percent reduction in seizure days per week for all 
seizure types was 38.08% (p < 0.0001) and the median dif-
ference in percent reduction in weekly seizure frequency for 
PGTC seizures was 30.35%. Only 33 patients experienced 
PGTC seizures (n = 15 for LEV, n = 18 for placebo), and the Neuropsychiatric Disease and Treatment 2007:3(4) 414
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difference did not reach statistical signiﬁ  cance. There was 
no difference between groups in median percent reduction 
of absence seizures (Andermann et al 2005).
In another double-blind study reported in a recent confer-
ence abstract, children and adults (age range = 4–65 years) 
with idiopathic generalized epilepsy received add-on LEV 
or placebo for PGTC seizures (Rosenfeld et al 2006). LEV 
was titrated over 4 weeks to a target dose of 3000 mg/day in 
adults and 60 mg/kg/day in children. Patients remained on a 
stable dose for 20 weeks. Among the 163 patients who were 
evaluable for efﬁ  cacy, 72.2% of the LEV group experienced 
at least a 50% reduction in PGTC seizures compared with 
45.2% of the placebo group (p = 0.0005). Complete seizure 
freedom was reported by 24.1% of patients on LEV therapy 
and 8.3% of patients on placebo (p = 0.009). Regulatory ap-
provals in PGTC seizures were based on this study.
Summary of LEV efﬁ  cacy in 
pediatric epilepsy and comparison 
with other AEDs
Table 1 provides a summary of LEV’s efﬁ  cacy from the 
pediatric studies reviewed above that included responder 
rates. Based on these studies, the median responder rate 
was 49% with most studies reporting a rate in the range of 
40%–60%. The median seizure-free rate was 8.4%. There 
was no clear difference in response based on seizure type. 
Among the 7 studies that evaluated differences based on 
seizure type, 3 found no difference, 1 found better efﬁ  cacy 
in generalized seizures, and 4 found better efﬁ  cacy for par-
tial seizures. A recently published consensus document that 
was based on the opinions of 39 physicians considered as 
experts in the treatment of pediatric epilepsy rated LEV’s 
usefulness (among other AEDs) in the treatment of various 
epilepsy types or syndromes and in particular clinical situa-
tions. LEV was rated as “usually appropriate” (ie, often used 
or ﬁ  rst-line choice) for cryptogenic complex partial seizures, 
and “sometimes appropriate” (ie, second-line choice) in 
Lennox-Gastaut syndrome, in juvenile myoclonic epilepsy, 
in myoclonic and generalized tonic-clonic seizures, and in 
newly diagnosed epilepsy in the emergency department 
(Wheless et al 2005).
It is not currently possible to make truly valid efﬁ  cacy 
comparisons between LEV and other AEDs since no head-
to-head studies in children have been completed. However, 
it may be instructive to review results across prospective, 
well-controlled, well-designed, appropriately-analyzed, 
double-blind trials (deﬁ  ned as class I evidence). A commit-
tee from the American Academy of Neurology (AAN) and 
the American Epilepsy Society (AES) has recently done just 
that. Based on their review, guidelines were published on the 
use of the newer AEDs in children with refractory partial 
epilepsy and 4 of the newer AEDs were recommended as 
adjunctive therapy based on data from class I trials (French et 
al 2004). A single class I trial was available for each of these 
4 AEDs. Class I evidence for LEV did not exist at the time of 
their review, but since that time it has become available and 
has been compared with the 4 newer AEDs recommended 
by AAN/AES (Table 2) (Verdru 2005). Review of the data 
in Table 2 suggests that the efﬁ  cacy of adjunctive LEV in 
children with refractory partial epilepsy may be comparable 
to that of three of the four recommended AEDs (topiramate 
[TPM], lamotrigine [LTG], and oxcarbazepine [OXC]) and 
is potentially better than the efﬁ  cacy of gabapentin (GBP).
Pediatric trials comparing AEDs directly are needed 
to determine which AEDs may be “ﬁ  rst-line” as add-on 
therapy or monotherapy for partial and generalized seizures 
in children. In an adult population, LEV has demonstrated 
similar efﬁ  cacy to CBZ-CR in a double-blind monotherapy 
trial in partial and generalized tonic-clonic seizures (Brodie 
et al 2007).
Safety and tolerability
Review of pediatric trials
LEV was generally well-tolerated in all of the pediatric 
studies reviewed above. Table 3 lists the overall AE rates, 
most common AEs, and any positive psychotropic effects 
that were reported in these trials. The overall incidence 
of AEs ranged from 4% to 88%. Interestingly, the highest 
rate (88%) was reported in the only double-blind trial for 
which AE rates were available. However, the placebo rate 
for AEs was even higher in this trial (92%). Somnolence 
(or other sedation-related AEs) was the most frequently 
reported AE across trials. Behavior-related problems were 
among the most commonly reported AEs in 7 of 12 trials. 
All 7 of these trials were open-label. A post-hoc analysis 
of the risk of neuropsychiatric AEs was undertaken in the 
double-blind pediatric study and determined that the risk 
was modestly increased in the LEV group relative to the 
placebo group (RR = 1.39; 95% CI: 0.93–2.08). Most of 
the events were categorized as mood/anxiety/behavioral 
problems. The relative risk was not increased in pediat-
ric patients with psychiatric histories or with cognitive 
impairment as compared to those without these comor-
bidities. Similarly, the relative risk for neuropsychiatric 
events in children was comparable to the relative risk in Neuropsychiatric Disease and Treatment 2007:3(4) 415
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Table 1 Efﬁ  cacy of adjunctive LEV in pediatric studies of refractory epilepsy
Study/Year  Study type  Seizure or   Responder   Seizure-   Efﬁ  cacy 
    epilepsy   rate (50%a) free  rate  differences 
   type      by  seizure 
         typeb
Andermann   Prospective,  Myoclonic  58.3%  NR  NR
et al 2005  double-blind,  (in JME)  (PLB = 23.3%)  
(n = 120)  PLB-controlled       
        
Glauser et al   Prospective,  Partial   44.6%  7%  NR
2006 double-blind,  only (PLB  = 19.6%)  (PLB = 1%) 
(n = 198)  PLB-controlled       
        
Rosenfeld    Prospective,  PGTC  72.2%  24.1%  NR
et al 2006  double-blind,  (in IGE)  (PLB = 45.2%) (PLB  =  8.3%) 
(n = 163)  PLB-controlled       
        
Glauser et al   Prospective,  Partial   52.2%  8.7%  SG>CP>SP
2002 Open-label  only    
(n = 24)         
Wheless and   Prospective,  Partial and   33.3%  7.7%  P > G
Ng 2002  open-label  generalized     
(n = 39)         
Lagae et al   Prospective,  Partial and   47%  4.8%  P = G
2003 open-label  generalized     
(n = 21)         
Grosso et al   Prospective,  Partial and   39%  9%  P > G
2005 open-label  generalized     
(n = 110)         
Lagae et al   Prospective,  Partial and   49%  5%  P = G
2005 open-label  generalized     
(n = 67)         
Opp et al   Retrospective,  Partial and   25%  6%  SG and SP 
2005 open-label  generalized      >  others
(n = 209)         
Herranz et al   Retrospective,  Partial and   65%  14%  P > G
2003 open-label  generalized     
(n = 43)         
Mandelbaum   Retrospective,  Partial and   53%  20%  G > P
et al 2005  open-label  generalized     
(n = 59)         
Tan and   Retrospective,  Partial and   61%  8%  P = G
Appleton,   open-label  generalized     
2004 (n = 26)         
Collins et al   Retrospective,  CP, GTC,   40%  20%   unable to 
2006 open-label  SG,  M      determine
(n = 20)    (in tuberous      
   sclerosis)     
aResponder rates were calculated as either the percent of patients with >50% seizure reduction or =50% seizure reduction. Additionally, rates may have been calculated 
over different durations of time and the methods for collecting seizure counts (diaries vs more subjective methods) may have differed between studies.
bDifferences in response rate based on seizure type were usually reported without any statistical analysis. Most investigators based their conclusions on an infor-
mal inspection of the data.
Abbreviations: CP, complex partial; G, generalized (all subtypes); GTC, generalized tonic-clonic; IGE, idiopathic generalized epilepsy; LEV, levitiracetam; M, myoclonic; JME, 
juvenile myoclonic epilepsies; PGTC, primary generalized tonic-clonic; PLB, placebo; P, partial (all subtypes); NR, not reported; SG, secondarily generalized; SP, simple partial.Neuropsychiatric Disease and Treatment 2007:3(4) 416
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adults that was calculated in a separate, double-blind, 
placebo-controlled study (Shoaf et al 2005).
Because of the lack of head-to-head trials, direct tolerability 
comparisons between AEDs, like efﬁ  cacy comparisons, are 
unavailable. However, the tolerability of LEV as reﬂ  ected by 
the withdrawal rate (due to AEs) from the placebo-controlled, 
double-blind trial (class I evidence) in patients 4–16 years old 
has been compared with those of the four other newer AEDs 
that were recommended by the AAN/AES committee (Verdru 
2005). Figure 3 depicts AE-related withdrawal rates (minus 
the rate in the placebo group) for class I trials of LEV, TPM, 
LMT, OXC, and GBP. Four percent fewer patients withdrew 
from the LEV group than from the placebo group. For TPM 
and LMT, withdrawals for AEs were also higher in the placebo 
group (by 2% and 1% respectively). In the OXC and GBP 
groups, the withdrawal rate was higher for patients receiving 
active drug (7% higher for OXC patients and 3% higher for 
GBP patients).
Seven of the 12 pediatric trials identiﬁ  ed for this review 
noted improvements in behavior or cognitive function dur-
ing LEV treatment (Table 3). Improvements occurred in 
9%–75% of patients, depending on the trial. In 2 of these tri-
als, neuropsychiatric status was monitored prospectively and 
systematically. Lagae and colleagues (Lagae et al 2005) used 
a structured questionnaire completed by caregivers because 
many of the children in their study were severely retarded 
and could not be tested quantitatively. Approximately one 
quarter of the patients were reported to show improvements 
in alertness or behavior. Improved alertness was usually 
observed as improved communication (verbal or non-verbal), 
and behavior was improved allowing better handling and 
structuring of the children. Improvement in behavior and 
cognition did not always correlate with improved seizure 
control. Over half the children with improvements had a 
seizure reduction of less than 50%.
In the Aeby et al study, children with CSWS were evalu-
ated using quantitative neuropsychological testing if they 
were capable of completing testing. Five of 7 patients tested 
showed improvements in at least 2 domains of cognitive 
function (eg, visual attention, visual or auditive memory, 
or graphic organization), and 6 of 7 demonstrated improved 
behavior during testing (Aeby et al 2005). In addition, all 
patients had behavior assessed by parents or teachers. In 7 
of 12 patients, better behavior was reported. Of the remain-
ing 5 patients, 3 were unchanged and 2 worsened. As in 
the Lagae et al study (Lagae et al 2005), improvements in 
cognitive function or behavior were not always associated 
with efﬁ  cacy improvements. Two of the nine patients who 
showed improvement in neuropsychologic testing or be-
havior as assessed by parents or teachers, did not show any 
improvement in EEG evaluation.
AEDs and cognitive development 
in children
Children may be more vulnerable to neurotoxic effects 
of drugs because of their developing nervous systems. In 
children of normal intellect, it is critical to control seizures 
without affecting cognitive development or learning ability. 
In children who are already cognitively impaired, further 
impairment must be avoided in order to maintain maximum 
function. Two clinical studies were designed speciﬁ  cally to 
evaluate the cognitive effects of LEV, although neither of 
these studies included children. In a double-blind crossover 
study of 10 healthy volunteers (mean age = 29.2 years), 
placebo, LEV, carbamazepine (CBZ), or OXC were admin-
istered for 8 days with a 2-week washout period between 
treatments (Mecarelli et al 2004). Doses were titrated over 
7 days to the ﬁ  nal dose of 750 mg bid for LEV, 400 mg bid 
for CBZ, and 600 mg bid for OXC. At baseline and 12 hours 
after the last dose of drug on day 8, neuropsychological test-
ing was performed. LEV did not have a negative impact on 
any on the tests employed, including measures of reaction 
time (motor task), selective attention (Stroop task), quanti-
tative EEG, or color visually evoked potentials (VEP). For 
CBZ, reaction time (motor speed) was signiﬁ  cantly slowed 
and delta and theta power (slowest frequency bands in the 
EEG) were increased, the frequency of the alpha rhythm 
was decreased, and P1 latency on VEP tests was slowed. 
These changes are indicative of CNS dysfunction and cog-
nitive slowing. OXC also demonstrated some signiﬁ  cant 
negative effects on EEG and VEP measures, but they were 
generally smaller and not as pervasive (ie, fewer measures 
Table 2 Results of class I trials of newer AEDs for refractory 
pediatric partial epilepsya
Drug-Placebo difference  LEV  TPM  LTG  OXC  GBP
Median % reduction in partial   27  22.6  29.4  26  10.5
seizures        
Responders (>50% seizure   25  19  26  19  3.7
reduction) (%)         
% Seizure free  6  5  NRb 3  2
aData are extracted from the single class I trial that has been reported for each 
AED. Adapted from Verdru P. 2005. Epilepsy in children: the evidence for new 
antiepileptic drugs. Acta neurol Scand: 112(Suppl 181):17-20. With permission from 
Blackwell Publishing.
Abbreviations: GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; NR, not 
reported; OXC, oxcarbazepine; TPM, topiramate.Neuropsychiatric Disease and Treatment 2007:3(4) 417
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Table 3 Tolerability of LEV in pediatric trials
Study/year  Study   Overall   Most common   Study   Positive 
 type  incidence    AEs  withdrawals  psychotropic 
  of  AEs      effects
Glauser et al   Open-label  not   headache  n = 2 (8%)  NR
2002   reported  infection (inefﬁ  cacy) 
(n = 24)      anorexia   
    somnolence   
Glauser et al   Double-blind  LEV: 88%  somnolence  LEV: n = 7   NR
2006    PLB: 92%   accidental   (7%) 
(n = 198)      injury  (5% for AEs) 
    vomiting   
      anorexia  PLB: n = 1 
    rhinitis  (14%) 
      (9%  for  AEs)
Wheless and   Open-label  51%  sedation  n = 14 (36%)  26% reported 
Ng 2002      aggression  (5% for AEs)  improved 
(n = 39)      hyperactivity    behavior 
    headache    and/or 
        cognition
Lagae et al   Open-label  19%  somnolence  n = 1 (5%)  19% reported 
2003     headache  (5%  for  AEs)  increased 
(n = 21)      behavior    alertness
Grosso et al   Open-label  14%  drowsiness  n = 65 (59%)a 17%  reported 
2005     nervousness  (3%  for  AEs)  better 
(n = 110)          behavior and 
        concentration
Lagae et al   Open-label  38%  tiredness  n = 18 (27%)  27% reported 
2005     aggressiveness  (3%  for  AEs)  increased
(n = 67)      headache    alertness,  
        24%  better
        behavior
Opp et al   Open-label  45%  somnolence  n = 170 (60%)  9% reported 
2005      aggression  (17% for   improvement 
(n = 285)b      loss of appetite  AEs)  in cognition, 
    sleep      speech,  mood, 
    disturbance    or  ataxia
Herranz et al   Open-label  28%  somnolence  overall rate   35% reported 
2003       not  reported  improvement 
(n = 43)        (5% for AEs)  in cognition 
        or  social 
        behavior 
Mandelbaum   Open-label  54% at    lethargy  n = 18 (31%)  not reported
et al 2005    3 months  behavior  (14% for  
(n = 59)    44% at     AEs) 
  12  months
Tan and   Open-label  4%  sleepiness  n = 5 (19%)  not reported
Appleton     (n = 1)    (4% for AEs) 
2004        
(n = 26)         
Collins et al   Open-label  75%  irritability/  n = 14 (70%)  not reported
2006   (in tuberous    agitation  (15% for AEs  
(n = 20)   sclerosis)    poor sleep  only) 
    aggression    continuedNeuropsychiatric Disease and Treatment 2007:3(4) 418
Wheless
were affected). A slower titration rate for CBZ may have 
produced fewer negative effects (Mecarelli et al 2004).
In another double-blind, crossover comparison in adult 
volunteers, CBZ and LEV were titrated more slowly (over 
4 weeks) and were then continued at a maintenance dose for 
4 weeks. The maintenance dose during the LEV arm was 
2000 mg/day, while the CBZ dose was adjusted to achieve 
midrange therapeutic level. Thirty-three cognitive and behav-
ioral variables were measured in 28 subjects after completion 
of the maintenance phase. Mean scores favored LEV over 
CBZ on 29 of 33 variables (88%), and the differences were 
statistically signiﬁ  cant for 14 of 33 variables (42%). CBZ was 
not signiﬁ  cantly better than LEV for any variable. Signiﬁ  -
cance was achieved for LEV on various cognitive and mood 
measures, including the proﬁ  le of mood states (POMS) and 
all 3 cognitive subscales (attention, language, and memory) 
of the QOLIE-89 (Quality of Life in Epilepsy, Long Form) 
(Meador et al 2006).
A recently published open-label study evaluated LEV’s 
effects on cognitive function in patients with refractory partial 
epilepsy (Piazzini et al 2006). A group of 35 adult patients 
who were receiving LEV in addition to a stable regimen of 
AEDs were compared with a control group (n = 35) on stable 
AED therapy. There was no difference between the groups as 
far as age, education or intelligence level, seizure frequency at 
baseline, duration of epilepsy, or number of AEDs at baseline 
Table 3 Tolerability of LEV in pediatric trials
Study/year  Study   Overall   Most common   Study   Positive 
 type  incidence    AEs  withdrawals  psychotropic 
  of  AEs      effects
Aeby et al   Open-label  not   dizziness  n = 4 (33%) at   75% with 
2005  (in CSWS)  reported    2 months    improved 
(n = 12)       (1  for  AE)  neuropsycho-
      n   = 8 (67%) by   logical 
        1 year (1 for   evaluation or 
      AEs)c  behavior at  
        2  months
aPatients with less than a 50% seizure reduction were discontinued except for 2 patients who were continued on LEV because of increased alertness.
bSafety population includes all patients on LEV, including those not evaluable for efﬁ  cacy and those on LEV monotherapy (n = 10).
cResults at 1 year are cumulative.
Abbreviations: AEs, adverse events; CSWS, slow-wave sleep; LEV, levetiracetam; NR, not reported; PLB, placebo.
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Figure 3 AE-related withdrawal rates in class 1 pediatric trials of newer AEDs (active minus placebo rates).
Abbreviations: AE, adverse events; AEDs, anti-epileptic drugs; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; TPM, topiramate.Neuropsychiatric Disease and Treatment 2007:3(4) 419
Levetiracetam for childhood epilepsy
(prior to addition of LEV). An extensive neuropsychological 
battery was administered to both groups of patients at base-
line and 7 weeks later, after the LEV add-on group had been 
titrated to a mean dose of 1834.3 mg/day (range = 1000–3500 
mg/day). Changes in cognitive performance from baseline 
were signiﬁ  cantly superior for 4 of 11 tests for the LEV add-
on group compared with controls. Signiﬁ  cant improvements 
were noted in 3 tests of attention and a test of oral ﬂ  uency. 
The control group was not superior to the LEV group on any 
cognitive measure. An analysis comparing LEV respond-
ers (n = 10) with LEV nonresponders (n = 25) detected no 
signiﬁ  cant difference in any test results, suggesting that the 
positive cognitive effects of LEV in this study were not just 
a result of seizure reduction (Piazzini et al 2006). A previous 
case study documented by some of the same researchers found 
improvements in verbal ﬂ  uency and complete abolishment 
of stuttering after 12 weeks of LEV therapy in a patient with 
baseline deﬁ  cits in verbal memory, oral comprehension, and 
verbal ﬂ  uency (Paola Canevini et al 2002).
Results of these clinical studies suggest that LEV does 
not negatively impact cognitive function in adults (on 
average) and has a better cognitive proﬁ  le than CBZ. The 
Piazzini et al study suggests that LEV has the potential to 
impart positive cognitive effects in some domains of cogni-
tive function. Preclinical studies in animal models are in 
agreement with these clinical ﬁ  ndings. LEV demonstrated 
no effect on cognitive function in normal or amygdala-
kindled rats in the Morris water maze test (Lamberty et al 
2000), no effect on attention in rats as measured by the 5-
choice serial reaction time task (Shannon and Love 2005), 
and no effect on working memory in rats as measured 
by spatial alternation performance (Shannon and Love 
2004). LEV showed positive effects on cognitive function 
by antagonizing the amnestic effects of scopolamine in 
passive avoidance learning in mice (Verloes et al 1988). 
Additionally, LEV has shown no evidence of neurotoxic 
effects at doses of 100 mg/kg in the developing rat brain (rat 
pups aged 0–7 days) (Manthey et al 2005). Formal, well-
controlled cognitive studies are needed to assess LEV’s 
cognitive proﬁ  le in children with epilepsy. A double-blind 
clinical trial in pediatric epilepsy is currently underway; 
however, no results are yet available.
AEDs and change in body weight
Several AEDs are known to either increase or decrease body 
weight, either of which may be undesirable in a develop-
ing child. Signiﬁ  cant weight changes may lead to health 
problems, poor self-esteem, and eventually, noncompli-
ance (Biton 2003). Valproate, CBZ, and GBP have been 
associated with weight gain, while TPM and zonisamide are 
associated with weight loss (Ness-Abramof and Apovian 
2005). Because body weight changes are common with 
some AED therapies, the effect of LEV therapy on weight 
was evaluated in a meta-analysis of controlled clinical tri-
als (Gidal et al 2003). There was no signiﬁ  cant difference 
in mean weight at baseline compared with mean weight at 
follow-up in 631 adult patients (after an average duration 
of 125 days of add-on LEV treatment). There was also 
no difference between LEV-treated patients and placebo-
treated patients in the incidence of clinically signiﬁ  cant 
weight changes (deﬁ  ned as >7% change from baseline). In 
the LEV group, 4.5% of patients had a weight increase and 
4.5% had a decrease. For placebo, 5.9% of patients had an 
increase vs 3.5% with a decrease. Similarly, LEV did not 
appear to affect body weight in a prospective, open-label 
trial of LEV in children with partial epilepsy. In this study, 
24 children aged 6–12 years were treated for up to 14 
weeks (only 2 patients did not complete 14 weeks). Three 
children (12.5%) had clinically signiﬁ  cant weight increases 
and 2 (8.3%) had clinically signiﬁ  cant weight loss (Glauser 
et al 2002). Based on these studies, LEV appears to be a 
weight-neutral AED.
AEDs and drug interactions
Children with refractory epilepsy often receive polytherapy 
with AEDs in order to adequately control seizures. Addition-
ally, children with epilepsy syndromes that include other 
medical manifestations as a part of the syndrome are also 
likely to receive polytherapy in order to control all aspects 
of the disorder. For these reasons, it is important to be aware 
of any drug-drug interactions between AEDs and cotherapy. 
A number of studies have evaluated the potential of LEV to 
interact with other AEDs or with other drugs that commonly 
participate in interactions. Based on these studies, it was 
determined that LEV does not participate in clinically sig-
niﬁ  cant pharmacokinetic interactions with other commonly 
prescribed AEDs (Perucca et al 2003), with low-dose oral 
contraceptives (Ragueneau-Majlessi et al 2002), with war-
farin (Ragueneau-Majlessi et al 2001), with digoxin (Levy 
et al 2001), or with probenecid (Patsalos 2000). Since LEV 
is not metabolized in the liver and is not appreciably protein 
bound it is unlikely to interact pharmacokinetically with any 
drugs (Patsalos 2000) and no signiﬁ  cant interactions have 
been reported (Perucca 2006). A pharmacodynamic interac-
tion has been reported between LEV and CBZ and between 
LEV and TPM (Patsalos 2003).Neuropsychiatric Disease and Treatment 2007:3(4) 420
Wheless
Other safety issues
Changes in laboratory parameters have been reported with 
AED treatment; therefore, these values are routinely tracked 
in clinical trials. Statistically signiﬁ  cant (compared with 
placebo) but clinically irrelevant changes in mean values 
for red blood cell (RBC) count, hematocrit, and hemoglobin 
have been reported for adult patients treated in clinical trials 
(Briggs and French 2004). Additionally, the incidence of 
possibly clinically signiﬁ  cant decreases in white blood cell 
(WBC) count and in neutrophil count was slightly higher 
in the LEV group (WBCs: LEV = 3.2%, placebo = 1.8%; 
neutrophils: LEV = 2.4%, placebo = 1.4%). (2004) In the 
double-blind pediatric trial in partial seizures, 3.0% of LEV 
patients vs 0% of placebo patients reported decreases in WBC 
count, but there was no apparent difference in the incidence 
of low neutrophil counts. No patients were discontinued for 
low WBCs or neutrophils. Meaningful changes in liver func-
tion tests or other blood chemistries have not been detected 
in LEV patients compared with placebo patients in adult 
or pediatric trials (Briggs and French 2004). Monitoring of 
laboratory values is not required.
Potential hypersensitivity reactions to LEV have 
been infrequently reported in clinical trials with an incidence 
similar to placebo (French et al 2001). Similarly, LEV use 
has not been associated with any idiosyncratic AEs in the 
currently published literature (Briggs and French 2004).
Summary and conclusions
LEV is a novel AED that binds to SV2A proteins and acts 
through a mechanism that is distinct from any other currently 
available AED. Its pharmacokinetic proﬁ  le allows easy ti-
tration with little risk for drug interactions. As adjunctive 
therapy, LEV appears to be safe and effective for the treat-
ment of pediatric epilepsy. Its efﬁ  cacy is best demonstrated 
in the treatment of partial seizures, but several studies show 
that LEV is efﬁ  cacious for a broad range of seizure types, 
including various subtypes of primary generalized seizures, 
and LEV is now approved for myoclonic and PGTC seizures. 
It has been well tolerated in pediatric studies with an AE 
proﬁ  le similar to that demonstrated in adults. Somnolence is 
the most commonly reported AE across all pediatric studies, 
and behavioral events were among the most common types 
of AEs in open-label studies. Improvements in behavior and 
cognition were also frequently reported. The relative risk of 
neuropsychiatric AEs appears similar in children compared 
with adults. The cognitive proﬁ  le of LEV as demonstrated 
in adults and in animal models is encouraging, but pediatric 
studies are needed.
In summary, LEV provides another much-needed option 
in the treatment of pediatric epilepsy. Further well-controlled 
studies are needed to fully deﬁ  ne its potential in generalized 
seizures and in children younger than 4 years old. 
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